west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "程序性死亡配体 1" 2 results
  • TSA-DC-CTL 细胞免疫治疗联合 PD-L1 抗体治疗高龄晚期结肠癌 1 例报道并文献复习

    目的报道 1 例肿瘤特异性抗原(TSA)刺激诱导树突状细胞(DC)及细胞毒性 T 淋巴细胞(CTL)过继治疗联合程序性死亡配体 1(PD-L1)抗体治疗高龄晚期结肠癌患者。方法2018 年 2 月笔者所在医院对 1 例 90 岁高龄女性患者因“回盲部癌伴梗阻”行剖腹探查、回盲部切除、小肠部分切除、末端回肠造瘘、腹膜活检术,肿瘤广泛转移,患者基础条件差,术后无法耐受常规治疗。经与患者家属充分沟通知情同意及解放军总医院伦理委员会批准,于术后 4 个月开始行 4 次 TSA-DC 细胞皮内多点注射,4 次 TSA-CTL 细胞静脉滴注,2 次 TSA-CTL 细胞腹腔注入,1 次 PD-L1 抗体 1 200 mg 静脉滴注。结果行 TSA-DC-CTL 联合 PD-L1 治疗后 7 d(治疗中期),患者的 KPS 评分升至 80 分(治疗前 40 分),外周血循环肿瘤细胞计数降至 7 个/3.2 mL(治疗前 16 个/3.2 mL),肿瘤标志物 CA125 降至 155.5 u/mL(治疗前 224.4 u/mL),治疗过程中未见相关不良反应。行 TSA-DC-CTL 联合 PD-L1 治疗后 36 d 患者突然出现血压和血氧饱和度下降,给与升压、兴奋呼吸等治疗,情况好转,因家属要求患者自动出院。结论TSA-DC-CTL 细胞免疫治疗联合 PD-L1 治疗本例高龄患者安全可行,能在一定程度上改善患者生活质量及部分生物学指标,但 TSA-DC-CTL 联合 PD-L1 抗体的安全性及近远期疗效有待进一步研究论证。

    Release date:2019-06-05 04:24 Export PDF Favorites Scan
  • Expression of PD-1/PD-L1 in esophageal squamous cell carcinoma and its relationship with survival prognosis: A systematic review and meta-analysis

    ObjectiveTo systematically evaluate the expression of programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in esophageal squamous cell carcinoma and its relationship with prognosis.MethodsThe literature from PubMed, EMbase, The Cochrane Library, Web of Science, CNKI and Wanfang data from inception to February 22, 2020 was searched by computer. Data were extracted and the quality of literature was evaluated using RevMan 5.3 software for meta-analysis. Egger's and Begg's tests were used to evaluate publication bias, and Stata 15.1 software was used for sensitivity analysis.Results A total of 16 articles were included, and there were 3 378 patients with esophageal squamous cell carcinoma. The methodological index for nonrandomized studies (MINORS) scores were all 12 points and above. The meta-analysis results showed that the positive expression rates of PD-1 and PD-L1 in tumor cells were 37.8% (190/504) and 41.7% (1 407/3 378), respectively. The positive expression of PD-L1 in tumor immune infiltrating cells was 41.7% (412/987). The overall survival (OS) of the tumor cell with high PD-L1 expression was lower than that with low PD-LI expression (HR=1.30, 95%CI 1.01-1.69, P=0.04). The OS of the tumor immune infiltrating cell with high PD-L1 expression was significantly higher than that with low PD-LI expression (HR=0.65, 95%CI 0.53-0.80, P<0.0001).ConclusionPD-L1 has a high expression rate in esophageal squamous cell carcinoma and is an important factor for the prognosis of esophageal squamous cell carcinoma.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content